Virus-like particles of hepatitis B virus core protein containing five mimotopes of infectious bursal disease virus (IBDV) protect chickens against IBDV

Vaccine

Volumn 30, Issue 12, 2012, Pages 2125-2130

  Wang, Yong Shan ^a   Ouyang, Wei ^a   Liu, Xiao Juan ^a,b   He, Kong Wang ^a   Yu, Sheng Qing ^c   Zhang, Hai Bin ^b   Fan, Hong Jie ^b   Lu, Cheng Ping ^b  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b NANJING AGRICULTURAL UNIVERSITY   (China)

^c INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

Chimeric VLP; Hepatitis B virus core particle; Infectious bursal disease virus; Mimotope vaccine; Virus like particle

Indexed keywords

ADJUVANT; BUFFER; EPITOPE; POLYPEPTIDE; RECOMBINANT VACCINE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; CHICKEN; CHIMERA; CONTROL GROUP; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENE EXPRESSION; HEPATITIS B VIRUS; IMMUNITY; IMMUNIZATION; IMMUNOREACTIVITY; INFECTIOUS BURSAL DISEASE; INFECTIOUS BURSAL DISEASE VIRUS; NONHUMAN; PLASMID; PRIORITY JOURNAL; RECOMBINANT GENE; SURVIVAL; VIRULENCE; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS STRAIN;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BIRNAVIRIDAE INFECTIONS; CHICKENS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; ESCHERICHIA COLI; GENE EXPRESSION; HEPATITIS B CORE ANTIGENS; INFECTIOUS BURSAL DISEASE VIRUS; INJECTIONS, INTRAMUSCULAR; NEUTRALIZATION TESTS; POULTRY DISEASES; RECOMBINANT PROTEINS; VACCINATION; VACCINES, SYNTHETIC; VACCINES, VIROSOME; VIRAL VACCINES;

EID: 84862813537     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.040     Document Type: Article

References (41)

1. Lukert P.D., Saif Y.M. Infectious bursal disease. Diseases of poultry 1997, 721-738. Iowa State University Press, Ames. 10th ed. B.W. Calnek (Ed.).
2. Muller H., Islam M.R., Raue R. Research on infectious bursal disease - the past, the present and the future. Vet Microbiol 2003, 97:153-165.
3. Jackwood D.J., Sommer S.E. Genetic heterogeneity in the VP2 gene of infectious bursal disease viruses detected in commercially reared chickens. Avian Dis 1998, 42:321-339.
4. Nagarajan M.M., Kibenge F.S. Infectious bursal disease virus: a review of molecular basis for variations in antigenicity and virulence. Can J Vet Res 1997, 61:81-88.
5. Snyder D.B., Lana D.P., Savage P.K., Yancey F.S., Mengel S.A., Marquardt W.W., et al. Differentiation of infectious bursal disease viruses directly from infected tissues with neutralizing monoclonal antibodies: evidence of a major antigenic shift in recent field isolates. Avian Dis 1988, 32:535-539.
6. Wang Y.S., Wang Z.C., Tang Y.D., Shi Z.L., He K.W., Li Y., et al. Comparison of four infectious bursal disease viruses isolated from different bird species. Arch Virol 2007, 152:1787-1797.
7. Kumar S., Ahi Y.S., Salunkhe S.S., Koul M., Tiwari A.K., Gupta P.K., et al. Effective protection by high efficiency bicistronic DNA vaccine against infectious bursal disease virus expressing VP2 protein and chicken IL-2. Vaccine 2009, 27:864-869.
8. Pitcovski J., Di-Castro D., Shaaltiel Y., Azriel A., Gutter B., Yarkoni E., et al. Insect cell-derived VP2 of infectious bursal disease virus confers protection against the disease in chickens. Avian Dis 1996, 40:753-761.
9. Rong J., Cheng T., Liu X., Jiang T., Gu H., Zou G., et al. Development of recombinant VP2 vaccine for the prevention of infectious bursal disease of chickens. Vaccine 2005, 23:4844-4851.
10. Zhou X., Wang D., Xiong J., Zhang P., Li Y., She R., et al. Protection of chickens, with or without maternal antibodies, against IBDV infection by a recombinant IBDV-VP2 protein. Vaccine 2010, 28:3990-3996.
11. Azad A.A., Fahey K.J., Barrett S.A., Erny K.M., Hudson P.J. Expression in Escherichia coli of cDNA fragments encoding the gene for the host-protective antigen of infectious bursal disease virus. Virology 1986, 149:190-198.
12. Macreadie I.G., Vaughan P.R., Chapman A.J., McKern N.M., Jagadish M.N., Heine H.G., et al. Passive protection against infectious bursal disease virus by viral VP2 expressed in yeast. Vaccine 1990, 8:549-552.
13. Ouyang W., Wang Y., Zhou Y., Zhang H., Tang Y. Recombinant Vp2 protein of infectious bursal disease virus AH1 strain expressed in insect cells: a vaccine candidate. Sheng Wu Gong Cheng Xue Bao 2010, 26:595-603.
14. Vakharia V.N., Snyder D.B., He J., Edwards G.H., Savage P.K., Mengel-Whereat S.A., et al. Infectious bursal disease virus structural proteins expressed in a baculovirus recombinant confer protection in chickens. J Gen Virol 1993, l74(Pt 6):1201-1206.
15. Fodor I., Horvath E., Fodor N., Nagy E., Rencendorsh A., Vakharia V.N., et al. Induction of protective immunity in chickens immunised with plasmid DNA encoding infectious bursal disease virus antigens. Acta Vet Hung 1999, 47:481-492.
16. Mahmood M.S., Siddique M., Hussain I., Khan A., Mansoor M.K. Protection capability of recombinant plasmid DNA vaccine containing VP2 gene of very virulent infectious bursal disease virus in chickens adjuvanted with CpG oligodeoxynucleotide. Vaccine 2006, 24:4838-4846.
17. Wang X., Jiang P., Deen S., Wu J., Liu X., Xu J., et al. Efficacy of DNA vaccines against infectious bursal disease virus in chickens enhanced by coadministration with CpG oligodeoxynucleotide. Avian Dis 2003, 47:1305-1312.
18. Huang Z., Elankumaran S., Yunus A.S., Samal S.K. A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV. J Virol 2004, 78:10054-10063.
19. Tsukamoto K., Kojima C., Komori Y., Tanimura N., Mase M., Yamaguchi S., et al. Protection of chickens against very virulent infectious bursal disease virus (IBDV) and Marek's disease virus (MDV) with a recombinant MDV expressing IBDV VP2. Virology 1999, 257:352-362.
20. Bublot M., Pritchard N., Le Gros F.X., Goutebroze S. Use of a vectored vaccine against infectious bursal disease of chickens in the face of high-titred maternally derived antibody. J Comp Pathol 2007, 137(Suppl. 1):S81-S84.
21. Pitcovski J., Gutter B., Gallili G., Goldway M., Perelman B., Gross G., et al. Development and large-scale use of recombinant VP2 vaccine for the prevention of infectious bursal disease of chickens. Vaccine 2003, 21:4736-4743.
22. Rong J., Jiang T., Cheng T., Shen M., Du Y., Li S., et al. Large-scale manufacture and use of recombinant VP2 vaccine against infectious bursal disease in chickens. Vaccine 2007, 25:7900-7908.
23. Wang Y.S., Fan H.J., Li Y., Shi Z.L., Pan Y., Lu C.P., et al. Development of a multi-mimotope peptide as a vaccine immunogen for infectious bursal disease virus. Vaccine 2007, 25:4447-4455.
24. Grgacic E.V., Anderson D.A. Virus-like particles: passport to immune recognition. Methods 2006, 40:60-65.
25. Roldao A., Mellado M.C., Castilho L.R., Carrondo M.J., Alves P.M. Virus-like particles in vaccine development. Expert Rev Vaccines 2010, 9:1149-1176.
26. Jegerlehner A., Storni T., Lipowsky G., Schmid M., Pumpens P., Bachmann M.F., et al. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol 2002, 32:3305-3314.
27. Pumpens P., Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 2001, 44:98-114.
28. Whitacre D.C., Lee B.O., Milich D.R. Use of hepadnavirus core proteins as vaccine platforms. Expert Rev Vaccines 2009, 8:1565-1573.
29. Crowther R.A., Kiselev N.A., Bottcher B., Berriman J.A., Borisova G.P., Ose V., et al. Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy. Cell 1994, 77:943-950.
30. Lee B.O., Tucker A., Frelin L., Sallberg M., Jones J., Peters C., et al. nteraction of the hepatitis B core antigen and the innate immune system. J Immunol 2009, 182:6670-6681.
31. Wynne S.A., Crowther R.A., Leslie A.G. The crystal structure of the human hepatitis B virus capsid. Mol Cell 1999, 3:771-780.
32. Cui Z.Z., Sun S.H., Shan Z.F., Jiang Y.W, et al. Pathogenicity of a very virulent strain GX8/99 of infectious bursal disease virus. Chin J Virol 2002, 18:162-166.
33. Karpenko L.I., Ivanisenko V.A., Pika I.A., Chikaev N.A., Eroshkin A.M., Veremeiko T.A., et al. Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble. Amino Acids 2000, 18:329-337.
34. Nassal M., Skamel C., Vogel M., Kratz P.A., Stehle T., Wallich R., et al. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines. Int J Med Microbiol 2008, 298:135-142.
35. Kratz P.A., Bottcher B., Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci USA 1999, 96:1915-1920.
36. Nassal M., Skamel C., Kratz P.A., Wallich R., Stehle T., Simon M.M., et al. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula. Eur J Immunol 2005, 35:655-665.
37. Skamel C., Ploss M., Bottcher B., Stehle T., Wallich R., Simon M.M., et al. Hepatitis B virus capsid-like particles can display the complete, dimeric outer surface protein C and stimulate production of protective antibody responses against Borrelia burgdorferi infection. J Biol Chem 2006, 281:17474-17481.
38. Zhang Y.L., Guo Y.J., Wang K.Y., Lu K., Li K., Zhu Y., et al. Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus. Scand J Immunol 2007, 65:320-328.
39. Ludwig C., Wagner R. Virus-like particles - universal molecular toolboxes. Curr Opin Biotechnol 2007, 18:537-545.
40. Garcon N., Wettendorff M., Van Mechelen M. Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin Biol Ther 2011, 11:667-677.
41. McKeage K., Romanowski B. Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix(R)). BioDrugs 2011, 25:265-269.